Filter
45
Filtered Results: 45
Text search:
Covishield
Featured
Recommendations
10
New Publications
15
Language
Document type
Guidelines
19
Fact sheets
10
Manuals
6
Studies & Reports
6
Situation Updates
2
Resource Platforms
1
Strategic & Response Plan
1
Countries / Regions
Argentina
12
Brazil
4
India
3
Latin America and the Carribbean
2
Ukraine
1
Syria
1
West and Central Africa
1
East and Southern Africa
1
South Sudan
1
Ecuador
1
Authors & Publishers
Publication Years
Category
COVID-19
24
Guidelines
8
Studies & Reports
3
Vaccine-preventable Diseases
2
Women & Child Health
2
Information, Education and Communication (IEC)
1
Statistics
1
Toolboxes
Country specific documents
17
Vaxzevria (Astra Zeneca)
12
Access & Strategy
5
Immunization Guidelines
5
Infection Control General
3
Educational Settings
3
Workplace
3
Physical Distancing
3
Context & Facts, Travel Advice
2
Moderna
2
Biontech/Pfizer Comirnaty
2
Booster Doses
2
Vaccination
1
Clinical Guidelines
1
Situation Reports & Updates
1
Prevention & Preparedness
1
COVID-19
1
For Pregnant Women
1
Country-specific Platforms
1
Vaccination & Strategy
1
Non-pharmaceutical interventions (NPIs)
1
Dashboards & Resource Platforms
1
Fair Allocation & Ethical Aspects
1
SARS-CoV-2 Variants
1
COVAX Initiative
1
Sputnik V
1
Research & Pipeline
1
Inactivated COVID-19 Vaccines
1
Guidelines & Manuals
1
General
1
Situation Reports & Updates
1
Considerations for implementing and adjusting public health and social measures in the context of COVID-19
recommended
interim guidance, 14 June 2021
This document is intended for national authorities and decision makers in countries that have introduced large scale public health and social measures. It offers guidance for adjusting public health and social measures, while managing the risk of a resurgence of cases...
Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respirato...
orientations provisoires, 14 juin 2021
Consideraciones para aplicar y ajustar medidas de salud pública y sociales en el contexto de la COVID-19
recommended
orientaciones provisionales, 14 de junio de 2021
interim guidance, 19 July 2021 (arabic version)
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Vaccinator's Manual. CONVIDECIA Vaccine
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
Considerations on the implementation and adjustment of
public health and social measures in the context of
COVID-19
Interim guidance 14 June 2021
COVID-19 Situation Update OPS/WHO Argentina: 10 February 2022
Situation report generated by the OPS/WHO representation in Argentina
Emergency medical teams (EMTs) play an important role in strengthening health service networks in terms of their strategies and tactics for planning mass vaccination programs, especially in remote or under-resourced areas or those overwhelmed by COVID-19. EMTs experience deploying in remote areas an...
COVID-19 Progress Report PAHO/WHO Argentina: 24 February 2022
Epidemiología; Resumen de puntos clave de conferencias y declaraciones de interés de OPS/OMS; Variantes de interés y preocupación; Actualización en vacunas; OPS/OMS en redes sociales; Publicaciones relacionadas; Noticias de la Regi...
This document provides guidance on interventions to prevent vaccine-preventable disease outbreaks in the context of mass population movement resulting from the ongoing crisis in Ukraine.
Campaña Nacional de Vacunación contra la COVID-19
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de...
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...
El siguiente manual se continuará actualizando, de ser necesario, a medida que se disponga de nueva información.
